Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Brinkhof, W. G. Martin; Egger, Matthias; Boulle, Andrew; May, Margaret; Hosseinipour, Mina; Sprinz, Eduardo

dc.contributor.author	Brinkhof, W. G. Martin
dc.contributor.author	Egger, Matthias
dc.contributor.author	Boulle, Andrew
dc.contributor.author	May, Margaret
dc.contributor.author	Hosseinipour, Mina
dc.contributor.author	Sprinz, Eduardo
dc.date.accessioned	2020-03-16T12:18:32Z
dc.date.available	2020-03-16T12:18:32Z
dc.date.issued	2007-12
dc.identifier.uri	http://ir.mu.ac.ke:8080/jspui/handle/123456789/3032
dc.description.abstract	We examined the incidence of and risk factors for tuber- culosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the inci- dence of tuberculosis associated with highly active antiret- roviral therapy was similar: the rate ratio for months 7–12 versus months 1–3 was 0.48 (95% confidence interval, 0.36– 0.64) in low-income countries and 0.36 (95% confidence in- terval, 0.26–0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings	en_US
dc.language.iso	en	en_US
dc.publisher	Ampath	en_US
dc.subject	Tuberculosis	en_US
dc.subject	Antiretroviral	en_US
dc.subject	Therapy	en_US
dc.subject	Low-Income	en_US
dc.subject	High-Income	en_US
dc.title	Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries	en_US
dc.type	Article	en_US